Skip to main content
Premium Trial:

Request an Annual Quote

AstraZeneca Modifies ARMS License to BTG and DxS; New Deal Enables Shops to Outlicense Tech

NEW YORK, Jan. 9 (GenomeWeb News) - AstraZeneca modified its agreement with BTG and DxS over licenses for the Amplification Refractory Mutation System, the companies said today.


Under the improved agreement, BTG and DxS can grant licenses to ARMS and related technologies to other companies.


The original agreement, signed in March 2004, gave BTG and DxS intellectual property rights to commercialize the technology within the diagnostic and research markets.


ARMS is used to detect gene mutations and SNPs.


Details on the agreement were not disclosed.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.